공고 • Jun 19
TenX Keane Acquisition announced that it has received $0.066667 million in funding TenX Keane Acquisition announced that it has received $66,667 in a round of funding from returning lender, Citius Pharmaceuticals, Inc. on June 17, 2024. The company has issued unsecured promissory note in the transaction. The note bears no interest and is repayable in full per the terms of the Merger Agreement. 공고 • May 17
TenX Keane Acquisition announced delayed 10-Q filing On 05/15/2024, TenX Keane Acquisition announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공고 • Apr 03
TenX Keane Acquisition announced delayed annual 10-K filing On 04/02/2024, TenX Keane Acquisition announced that they will be unable to file their next 10-K by the deadline required by the SEC. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. CFO & Executive Director Taylor Zhang was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공고 • Jan 19
TenX Keane Acquisition announced that it has received $0.2 million in funding TenX Keane Acquisition announced that it has raised $200,000 in a debt round of funding from new lender Citius Pharmaceuticals, Inc. on January 17, 2024. The company has issued Non Convertible Zero Coupon Promissory Note in the transaction. The note bears no interest and is repayable in full per the terms of the Merger Agreement. 공고 • Nov 15
TenX Keane Acquisition announced delayed 10-Q filing On 11/14/2023, TenX Keane Acquisition announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공고 • Oct 26
Citius Oncology, Inc. entered into an agreement and plan of merger to acquire TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP and others for approximately $730 million in a reverse merger transaction. Citius Oncology, Inc. entered into an agreement and plan of merger to acquire TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP and others for approximately $730 million in a reverse merger transaction on October 23, 2023. Combined public company will be named Citius Oncology, Inc. Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in the combined company and retain majority ownership of approximately 90% and TenX expected to own approximately 10% of Citius Oncology. Myron Holubiak will serve as Executive Vice Chairman of the Citius Oncology Board of Directors. In case of termination under certain circumstances, Citius Pharma to pay a $5,000,000 Termination Fee to TenX.Transaction is subject to approval by stockholders of TenX; all requisite regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder, have been obtained and remain in full force and effect and all statutory waiting periods in respect thereof have expired or been terminated; the registration statement and proxy statement/prospectus becoming effective under the Securities Act of 1933, as amended; TenX having at least $5,000,001 in net tangible assets and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both companies. Citius Pharma, as the sole holder of Citius Oncology common stock, has approved the transaction. Transaction is expected to close in the first half of 2024.Maxim Group LLC is acting as exclusive financial advisor to Citius Pharma and Newbridge Securities Corporation is acting as exclusive financial advisor to TenX. David Creekman and Alec Donaldson of Wyrick Robbins Yates & Ponton LLP acting as legal advisors to Citius Pharma. Tammara Fort and Samara Thomas of The Crone Law Group P.C. acting as legal advisors to TenX. American Stock Transfer & Trust Company, LLC is acting as exchange agent for TenX. 공고 • Oct 19
TenX Keane Acquisition announced that it has received $0.66 million in funding from 10XYZ Holdings LP TenX Keane Acquisition announced that it has issued an unsecured non-convertible promissory note for aggregate proceeds of $660,000 on October 18, 2023. The transaction included participation from returning investor 10XYZ Holdings LP. The note bears no interest and is payable in full upon the consummation of the company’s business combination. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date; (ii) the commencement of a voluntary or involuntary bankruptcy action, (iii) the breach of the company’s obligations thereunder; (iv) any cross defaults; (v) an enforcement proceedings against the Company; and (vi) any unlawfulness and invalidity in connection with the performance of the obligations thereunder, in which case the Promissory Note may be accelerated. 공고 • Aug 17
TenX Keane Acquisition announced delayed 10-Q filing On 08/15/2023, TenX Keane Acquisition announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 
